13 February 2024
13 February 2024
At the ongoing SCOPE Summit 2024, experts are no longer asking if artificial intelligence (AI) can assist in clinical trials, but if it should it be.
Larimar has reported positive Phase II data for its Friedreich’s ataxia drug and plans to start a confirmatory trial, intending to file a biologics licence application (BLA) in H2 2025.
The platform provides access and insight to speed up clinical development and therapeutic innovation.
The trial initiation is supported by a $2m grant from NIH Small Business Innovation Research.
The pause was initiated following data from the Phase II trial that suggested potentially lower than expected efficacy.
The trial did not meet the primary efficacy endpoint of mean change in the Cohen-Mansfield Agitation Inventory total score.
GlobalData epidemiologists currently predict that the diagnosed prevalent cases of Alzheimer’s in the UK in 2024 will be approximately 330,000, which will increase to approximately 350,000 cases in 2028.
RadioMedix and Orano Med’s radioligand therapy AlphaMedix (lead-212-Dotamtate) is currently in a Phase II trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
